VANCOUVER, BRITISH COLUMBIA -- (Marketwire) -- 12/14/12 -- biOasis Technologies Inc. (TSX VENTURE: BTI) today is pleased to provide a 2012 year in review. biOasis has come a long way in 2012. The company has enjoyed a steady, measured progression towards its goals in the execution of its science and business objectives.
Through 2012 the company developed a powerful network of highly respected contract research organizations that have helped conduct research, evaluate and most importantly, validate biOasis' technology in pre-clinical studies. The results of this work have positioned biOasis as an attractive partner for major pharmaceutical companies working in the CNS sector. To this end, we have entered into four collaborations with top tier pharmaceutical companies in England, Belgium and the USA.
"I am very happy to give current investors and those who might consider biOasis as part of their investment portfolio a brief, snap shot view of 2012 . . . its not an easy assignment as the challenge is to provide this in a brief form," says CEO Rob Hutchison. "Our advancements over the past year have been so important that it is difficult to condense them without leaving important points out". "What the following reveals is a company that is moving forward with resolve."
From its public inception in March 2008 to June of 2012, biOasis was very much focused on validating its technology. Although our core technologies had been vetted with solid research at The University of British Columbia amongst others, it was important for biOasis to both affirm and advance our technology base with additional scientific institutions and industrial partner organizations. This was a critical step that was key to enable us to take the technology to potential pharmaceutical partners - and attract the interest of those potential partners to want to evaluate our technology for themselves.
Throughout 2012 we made some significant advances in understanding the potential of our blood-brain barrier delivery technology. For example, we observed that our Transcend vector can carry very large therapeutics, such as antibodies to treat metastatic breast cancer, across the blood-brain barrier. World-renowned experts at Texas Tech University, using specialized techniques, showed higher transport rates than our initial findings. In addition, studies conducted by third parties in 2012, showed that several other therapeutic compounds could be transported across the blood-brain barrier.
With this knowledge and data in hand we created a non-confidential information package that we began to circulate within the biopharmaceutical sector. The interest thus generated has been remarkably strong. In the year 2012 alone we've entered into collaboration agreements with four top tier pharmaceutical companies. biOasis could not be happier with the companies so far on board and with the continued industry interest leading into 2013. We've been asked by many of you, "how long is the collaboration process?" Although varied and of different time frames, the collaborative agreements are key to moving biOasis to the next evolutionary phase of our business - seeing our technology migrate from us to our pharmaceutical partners.
Most Popular Stories
- SEO Traffic Lab Celebrate Wins at Digital Marketing Event 'Internet World 2013' in London
- Social Media Initiatives Should Follow Customers' Lead
- Apple CEO: Offshore Units Not a 'Tax Gimmick'
- U.S. Senate Accuses Apple of Large-scale Tax Avoidance
- UTEP Water Recycling Project Wins Venture Titles
- Marketo Makes a Mint in IPO: Stock Shoots Up More than 50 Percent
- Bieber Booed at Billboard Awards
- Crude Oil Up, Gasoline Down
- Austin Startup Compare Metrics Raises $3.5 Million for Expansion
- Why So Many Top 'Car Guys' Are Actually Women